Global Uveitis Market 2014-2018 - KYTX CBS 19 Tyler Longview News Weather Sports

Global Uveitis Market 2014-2018

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE Research and Markets

DUBLIN, June 24, 2014 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/f9mqvw/global_uveitis) has announced the addition of the "Global Uveitis Market 2014-2018" report to their offering.

http://photos.prnewswire.com/prnh/20130307/600769

Currently, the current competition in the Global Uveitis market is weak and the available treatment options have only been moderately successful in meeting market demand. The current market is served in the main by three approved products namely Alcon Laboratories's Durezol, Allergan's Ozurdex, and Bausch & Lomb's Retisert.

The expected entry of new players such as Lux Biosciences's Luveniq (NDA filled), pSivida Corp.'s Medidur (phase III), and Santen Pharmaceutical Co. Ltd.'s DE-109 (phase III) within the forecast period is expected to intensify the competition in future. The products currently available in the market are associated with low safety and as those products do not serve the market's unmet need, the market continues to present opportunities for stronger pipeline candidates.

According to the report, one of the main drivers in this market is the increasing prevalence of eye disorders around the world, which has consequently led to a rise in the incidence of uveitis. Uveitis is responsible for approximately 5 to 20 percent of legal blindness in western countries and approximately 25 percent of blindness in the developing world.

Key Topics Covered:

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

04. Product Profiles

05. Market Research Methodology

06. Introduction

07. Market Landscape

08. Treatment Options for Uveitis

09. Pipeline Snapshot

10. Rate of Incidence and Prevalence

11. Geographical Segmentation

12. Buying Criteria

13. Market Growth Drivers

14. Drivers and their Impact

15. Market Challenges

16. Impact of Drivers and Challenges

17. Market Trends

18. Trends and their Impact

19. Vendor Landscape

20. Key Vendor Analysis

21. Other Reports in this Series

Companies Mentioned:

  • Abbvie Inc.
  • Alcon Laboratories Inc.
  • Allergan Inc.
  • Bausch & Lomb Inc.
  • Artielle ImmunoTherapeutics Inc.
  • Enzo Biochem Inc.
  • Hanall Pharmaceutical Co. Ltd.
  • Lux Biosciences Inc.
  • OphthaliX Inc.
  • Regeneron Pharmaceuticals Inc.
  • TopiVertLtd.
  • pSivida Corp.
  • XOMA Corp.
  • Santen Pharmaceutical Co.

For more information visit http://www.researchandmarkets.com/research/f9mqvw/global_uveitis

Media Contact: Laura Wood , +353-1-481-1716, press@researchandmarkets.net

©2012 PR Newswire. All Rights Reserved.

Powered by WorldNow

CBS19, MYTX & KCEB
2211 ESE Loop 323
Tyler, TX 75701
Phone (903) 581-2211
Fax (903) 581-5769

Powered by WorldNow
All content © Copyright 2000 - 2014 WorldNow and KYTX. All Rights Reserved. Users of this site agree to the Terms of Service, Privacy Notice/Your California Privacy Rights, and Ad Choices.